299 related articles for article (PubMed ID: 16740036)
21. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
[TBL] [Abstract][Full Text] [Related]
22. Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa.
Cohen PR; Rapin RP; Farhood AI
Am J Dermatopathol; 1994 Oct; 16(5):573-4. PubMed ID: 7528477
[No Abstract] [Full Text] [Related]
23. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression.
Sasaki M; Ishida T; Horiuchi H; MacHinami R
Pathol Int; 1999 Sep; 49(9):799-806. PubMed ID: 10504551
[TBL] [Abstract][Full Text] [Related]
24. p53 protein immunoreactivity in fibrohistiocytic tumors of the skin.
Lee CS; Chou ST
Pathology; 1998 Aug; 30(3):272-5. PubMed ID: 9770192
[TBL] [Abstract][Full Text] [Related]
25. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Abenoza P; Lillemoe T
Am J Dermatopathol; 1993 Oct; 15(5):429-34. PubMed ID: 7694515
[TBL] [Abstract][Full Text] [Related]
26. Prominent myofibroblastic differentiation. A pitfall in the diagnosis of dermatofibroma.
Zelger BW; Zelger BG; Rappersberger K
Am J Dermatopathol; 1997 Apr; 19(2):138-46. PubMed ID: 9129698
[TBL] [Abstract][Full Text] [Related]
27. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
Wick MR; Ritter JH; Lind AC; Swanson PE
Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
[TBL] [Abstract][Full Text] [Related]
28. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
29. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Calikoglu E; Augsburger E; Chavaz P; Saurat JH; Kaya G
J Cutan Pathol; 2003 Mar; 30(3):185-9. PubMed ID: 12641778
[TBL] [Abstract][Full Text] [Related]
30. When Immunohistochemistry Deceives Us: The Pitfalls of CD34 and Factor XIIIa Stains in Dermatofibroma and Dermatofibrosarcoma Protuberans.
John AM; Holahan HH; Singh P; Handler MZ; Lambert WC
Skinmed; 2017; 15(1):53-55. PubMed ID: 28270311
[No Abstract] [Full Text] [Related]
31. Comparison of p53 expression in dermatofibrosarcoma protuberans and dermatofibroma: lack of correlation with proliferation rate.
Díaz-Cascajo C; Bastida-Iñarrea J; Borrego L; Carretero-Hernández G
J Cutan Pathol; 1995 Aug; 22(4):304-9. PubMed ID: 7499569
[TBL] [Abstract][Full Text] [Related]
32. Atypical dermatofibroma with predominant epithelioid/deciduoid-like cell component. Histogenetic considerations in the wide spectrum of fibrohistiocytic dermal tumours.
Amico P; Vecchio GM; Bisceglia M; Vasquez E; Magro G
Pathologica; 2010 Jun; 102(3):115-8. PubMed ID: 21171517
[TBL] [Abstract][Full Text] [Related]
33. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
34. The value of immunohistochemistry in atypical cutaneous fibrous histiocytoma.
Wilk M; Zelger BG; Nilles M; Zelger B
Am J Dermatopathol; 2004 Oct; 26(5):367-71. PubMed ID: 15365367
[TBL] [Abstract][Full Text] [Related]
35. Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles.
Hsi ED; Nickoloff BJ
J Dermatol Sci; 1996 Jan; 11(1):1-9. PubMed ID: 8867761
[TBL] [Abstract][Full Text] [Related]
36. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.
Mori T; Misago N; Yamamoto O; Toda S; Narisawa Y
J Dermatol; 2008 Jul; 35(7):419-25. PubMed ID: 18705829
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
Taniuchi K; Yamada Y; Nonomura A; Takehara K
J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical observation of intracytoplasmic lysozyme in proliferative and neoplastic fibrohistiocytic lesions.
Nakanishi S; Shinomiya S; Sano T; Hizawa K
Acta Pathol Jpn; 1982 Nov; 32(6):949-59. PubMed ID: 6297236
[TBL] [Abstract][Full Text] [Related]
39. Possible contribution of PDGF-BB-induced autophagy in dermatofibrosarcoma protuberans: Autophagy marker Atg5 could be a differential marker between dermatofibrosarcoma protuberans and dermatofibroma.
Motegi SI; Fujiwara C; Sekiguchi A; Yamazaki S; Yokoyama Y; Yasuda M; Ishikawa O
J Dermatol Sci; 2019 Feb; 93(2):139-141. PubMed ID: 30704939
[No Abstract] [Full Text] [Related]
40. Fibrous and fibrohistiocytic neoplasms: an update.
Clarke LE
Dermatol Clin; 2012 Oct; 30(4):643-56, vi. PubMed ID: 23021051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
